LL-37: Reference Overview and Reconstitution Notes

LL-37 is a human peptide belonging to a family called cathelicidins. A peptide is a short chain of amino acids, which are the building blocks that make up proteins. LL-37 is grouped under immune and host-defense research. It is a research-only compound and is not approved by the FDA for any therapeutic use.

LL-37

What it is

LL-37 is the only known human member of a natural defense protein family called cathelicidins. It is a short chain of 37 amino acids (amino acids are the building blocks that proteins are made from). It carries a positive electrical charge and has a shape that lets it interact with both water and fats. The body releases LL-37 from a larger starting protein called hCAP18. Cells such as neutrophils (a type of white blood cell), skin-lining cells, and other cell types all produce it as part of the body's built-in first line of defense.

Research context and categorization

Key point: LL-37 is an investigational compound with no approved therapeutic uses. It is studied mainly in lab dishes and test tubes (called in vitro studies) and in animal studies for its host-defense and tissue-repair properties.

LL-37 is generally grouped under the immune and host-defense category of research peptides. It is also discussed in relation to healing and tissue repair.

Key Areas of Investigation

In neutral research terms, scientists investigate LL-37 for its broad lab-based antimicrobial activity (the ability to act against microbes) against two main classes of bacteria. Gram-positive bacteria have a thick outer wall. Gram-negative bacteria have a thinner wall but an added outer layer. LL-37 is also studied against some viruses and fungi, and for its ability to break up biofilms. A biofilm is the protective slime layer that bacteria build around themselves, similar to the film that forms on teeth before brushing.

Researchers also study LL-37 in relation to immune signaling and the body's inflammatory response. It is investigated for wound-repair-related processes, including how skin cells move to cover a wound, how new tiny blood vessels form, and how skin-lining cells multiply. These studies take place in the laboratory and in early animal research.

Scientific Hurdles and Limitations

All of these uses are strictly investigational. LL-37 is not an approved therapy for any of these applications. The effects described are observed in research models and are not confirmed benefits in humans.

Research also notes practical challenges for any applied use. One is limited stability when the body's enzymes try to break it down. Another is that it can harm cells at higher concentrations. These issues are part of why much research focuses on modified versions of LL-37 rather than the original peptide.

Status

• Regulatory status: Research-only. LL-37 is not FDA-approved and has no formal FDA classification for therapeutic or compounding use. It is considered an investigational compound.
• Sport status: LL-37 is not listed by name on the WADA Prohibited List. However, WADA's S0 category ("non-approved substances") is a broad catch-all that covers any pharmacological substance not currently approved by a government regulatory authority for human therapeutic use. An unapproved peptide like LL-37 can fall under that broad prohibition. Anyone subject to testing should confirm the current status with their governing body.

Reconstitution notes (general)

Freeze-dried (lyophilized) peptide is typically reconstituted (dissolved back into liquid) using bacteriostatic water. Bacteriostatic water is water that contains a small amount of preservative to slow bacterial growth. The concentration you end up with equals the amount of peptide in the vial divided by the volume of water you add.

For example, the same amount of powder dissolved in a larger volume of water gives a lower concentration, while a smaller volume gives a higher concentration. To work out a target concentration for any vial size, use the reconstitution calculator at peptide calculator.

Dilution and handling notes (compound-specific)

LL-37 comes as a freeze-dried powder and dissolves readily in water, so it generally goes into bacteriostatic water without much difficulty. That said, it tends to interact with surfaces and clump together, so a few specific handling points apply.

Solubility and Concentration

LL-37 carries a strong net positive charge. Think of it like tiny magnets: when the solution has low salt content, the positive charges on the peptide molecules push each other apart and keep them dissolved. When the salt content is high, or when the concentration is very high, that repulsion weakens. The molecules can then bump into each other and clump, causing cloudiness or visible particles.

For this reason, reference handling tends to favor lower concentrations. Published lab work and early topical research has used relatively low concentrations, roughly in the range of 0.5 to 1.6 mg/mL. This reflects both good dissolving at those levels and the fact that higher concentrations can harm cells.

Key Handling Guidelines

• Managing cloudiness: If cloudiness appears, the usual fixes are to reconstitute at a lower concentration and to use a low-salt diluent rather than concentrated salt-based buffers.
• Surface adsorption: Because LL-37 is positively charged and interacts with both water and fats, it can stick to glass and plastic surfaces. This can reduce the actual amount of peptide in very dilute preparations. For this reason, low-binding labware (lab containers specially treated to reduce sticking) is often preferred.
• Reconstitution technique: LL-37 foams easily. Direct the diluent slowly down the inside wall of the vial rather than squirting it straight onto the powder. Swirl gently instead of shaking, and avoid repeatedly freezing and thawing the vial.

Structural Characteristics

In plain water, LL-37 is largely unstructured (loosely shaped, like a limp noodle). It only folds into its characteristic curved spiral shape (called an alpha-helix) when it enters an environment that mimics a cell membrane. This is a common observation in the scientific literature on how the peptide behaves.

Handling and storage

Store the reconstituted vial in a refrigerator at 2 to 8 degrees Celsius and keep it away from direct light. Wipe the stopper with an alcohol swab before each access, and label the vial with the date it was mixed.

A reconstituted, refrigerated peptide is commonly treated as usable for about four weeks. Discard the solution if it becomes cloudy or discolored, or if you see visible particles or floaters in it.

Related reading

• Matrixyl
• Melanotan II
• MGF (Mechano Growth Factor)
• How Reconstitution Works
• How Long Does a Reconstituted Vial Last?

Tools and supplies

• peptide calculator
• Bacteriostatic Water 30 ml
• Gansulin Metal Reusable Pen
• 3 ml Glass Cartridges (10-pack)
• Complete Starter Kit

Reminder: research and educational reference only. Preppin Peppers sells hardware and materials, not peptides. Not medical, dosing, or health advice, not evaluated by the FDA, and not intended for human or animal use.

Frequently asked questions

What is LL-37 and what peptide family does it belong to?

LL-37 is the only known human cathelicidin , a 37-amino-acid cationic host-defense peptide cleaved from the precursor protein hCAP18 by neutrophils and epithelial cells. It is investigational with no FDA-approved therapeutic use.

What does current LL-37 research investigate?

Lab and animal studies examine LL-37 for broad-spectrum antimicrobial activity against gram-positive and gram-negative bacteria, biofilm disruption, immune signaling modulation, and wound-repair processes such as cell migration and angiogenesis.

How is lyophilized LL-37 reconstituted for laboratory use?

Standard lab practice is to add bacteriostatic water slowly to the freeze-dried vial via a reconstitution pen or syringe, gently swirl until the solution is clear, label with the reconstitution date, and store refrigerated. Do not shake.

What the research community gets wrong about LL-37 handling

LL-37 is a small, strongly positive peptide, and that charge is behind most of the handling surprises reported in the literature. A few points come up again and again in bench work.

• Assuming the vial holds all the peptide it started with. Peptides and proteins stick to the walls of tubes, tips, and vials, and this loss is worst at low concentrations. In one analysis, a peptide was almost entirely lost to the walls of ordinary vials before it could even be measured. For very dilute LL-37 stocks, the amount actually left in solution can be lower than the label suggests.
• Skipping low-binding labware. Switching from standard tubes to low-binding vials restored clean, linear peptide measurements in the same study. Because LL-37 is cationic and interacts with both water and fats, low-binding polypropylene tubes are a simple way to reduce how much sticks to glass and plastic.
• Reconstituting or storing near neutral pH. LL-37 tends to clump together as the pH rises toward neutral. Bench guidance is to keep concentrated stocks slightly acidic and only bring the pH up after diluting into a working solution, rather than at the concentrated stage.
• Going too concentrated. The peptide dissolves well when the charges on each molecule can push the molecules apart, which happens best at lower salt and lower concentration. Very high stock concentrations make clumping and cloudiness more likely, so lower-concentration stocks are easier to keep clear.
• Repeated freeze and thaw. Each freeze-thaw cycle is another chance for the peptide to aggregate. Working from single-use aliquots avoids putting the whole batch through that stress over and over.

From our bench, the LL-37 lesson we keep relearning is to treat the surfaces, not just the powder. When a dilute preparation reads lower than expected on a rough check, our first suspect is the tube wall rather than the peptide itself, and moving to low-binding tubes and gentler transfers usually settles it. We work with LL-37 only as a research material for reconstitution and handling notes, and nothing here is a dosing or health claim.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. Vandamme et al., Cell Immunol 2012 , Cathelicidin LL-37: An Antimicrobial Peptide with a Role in Inflammatory Skin Disease (PMC3346901)
5. UniProtKB P49913 (CAMP_HUMAN) , Cathelicidin antimicrobial peptide / LL-37, precursor hCAP-18
6. Improved intact peptide and protein quantitation by LC-MS: battling the deleterious effects of analyte adsorption (PMC10989528)